DEVELOPMENT OF A LIPOSOMAL DRUG CARRIER TO DELIVER SUFFICIENT ANTI-CANCER DRUG INTO MULTI DRUG RESISTANT (MDR)-SMALL CELL LUNG CANCER (SCLC)

摘要

Development of distant metastases and acquired multidrug resistance (MDR) are major problem in the therapy for human small cell lung cancer (SCLC). In this study, we demonstrated the possibility that transferrin (TF)-grafted liposomes may be available to deliver sufficient anti-cancer drug, doxorubicin (DXR), into MDR-SCLC (SBC-3/ADM), overexpressed P-glycoprotein (P-gp).